A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

NCT06733233 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer, Estrogen Receptor-Positive
HER2 Low Breast Cancer

Interventions

DRUG: T-DXd combined with immune checkpoint inhibitor

Sponsor

Guangzhou Women and Children's Medical Center